HC Wainwright Issues Negative Forecast for DBVT Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for DBV Technologies to ($1.65), down from the previous estimate of ($1.45), while maintaining a "Buy" rating with a target price of $16.00.
• DBV Technologies reported a quarterly loss of ($1.55) EPS, significantly missing analysts' consensus estimates, with a revenue of $1.74 million compared to expected $0.64 million.
• The company's stock recently dropped 9.5% and has a market capitalization of $233.09 million, with a consensus rating of "Moderate Buy" and target price of $14.75.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of DBV Technologies in a research report issued on Wednesday, July 30th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($1.65) per share for the quarter, down from their prior forecast of ($1.45). HC Wainwright currently has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies' Q4 2025 earnings at ($1.70) EPS, FY2025 earnings at ($6.30) EPS, FY2026 earnings at ($6.25) EPS, FY2027 earnings at ($5.90) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at $0.75 EPS.

DBVT has been the topic of a number of other reports. JMP Securities reissued a "market outperform" rating and issued a $21.00 price objective on shares of DBV Technologies in a report on Thursday, June 26th. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. Finally, The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a report on Thursday, May 29th. Two equities research analysts have rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.75.

DBV Technologies Price Performance

DBV Technologies stock traded up $0.69 during midday trading on Friday, reaching $9.50. The company's stock had a trading volume of 28,869 shares, compared to its average volume of 216,966. The stock's 50-day simple moving average is $9.50 and its 200-day simple moving average is $7.48. The stock has a market capitalization of $260.21 million, a P/E ratio of -1.99 and a beta of -0.58. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The business had revenue of $1.74 million during the quarter, compared to analysts' expectations of $0.64 million.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.